SCHEMBL4311285

SCHEMBL4311285

CCn1cc(-c2ccnc3[nH]c(-c4ccc(CN(C)C)cc4)cc23)c(-c2ccc(N)cc2)n1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AURKA O14965 19/20 0.75
▸ AURKB Q96GD4 19/20 0.75
▸ INCENP Q9NQS7 2/20 0.64
▸ TPX2 Q9ULW0 2/20 0.64
▸ PLK4 O00444 1/20 0.64
▸ CIT O14578 1/20 0.64
▸ EPHB6 O15197 1/20 0.64
▸ RIPK2 O43353 1/20 0.64
▸ ROCK2 O75116 1/20 0.64
▸ PRKD3 O94806 1/20 0.64
▸ MAP4K4 O95819 1/20 0.64
▸ NTRK1 P04629 1/20 0.64
▸ RET P07949 1/20 0.64
▸ CYP3A4 P08684 1/20 0.64
▸ CYP2D6 P10635 1/20 0.64
▸ FGFR1 P11362 1/20 0.64
▸ CYP2C9 P11712 1/20 0.64
▸ FLT1 P17948 1/20 0.64
▸ FECH P22830 1/20 0.64
▸ DCK P27707 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14160547 0.91 AURKA (0.69) AURKAAURKBINCENPTPX2PLK4
SCHEMBL4313520 0.91 AURKA (0.76) AURKAAURKBINCENPTPX2PLK4
SCHEMBL4316892 0.91 AURKA (0.74) AURKAAURKBINCENPTPX2PLK4
SCHEMBL4311298 0.89 AURKA (0.64) AURKAAURKBINCENPTPX2PLK4
SCHEMBL4310369 0.87 AURKA (0.66) AURKAAURKBINCENPTPX2PLK4
SCHEMBL4313565 0.87 AURKA (0.58) AURKAAURKBINCENPTPX2PLK4
SCHEMBL27735461 0.86 AURKA (0.73) AURKAAURKBINCENPTPX2PLK4
SCHEMBL4310001 0.86 AURKB (1.00) AURKAAURKBINCENPTPX2PLK4
SCHEMBL4310379 0.85 AURKA (0.63) AURKAAURKBINCENPTPX2PLK4
SCHEMBL4305200 0.85 AURKA (0.74) AURKAAURKBINCENPTPX2PLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1962830-B1 AZAINDOLE INHIBITORS OF AURORA KINASES GLAXOSMITHKLINE LLC (US) 2013-03-27 — — EP disclosed
US-7605266-B2 Azaindole inhibitors of Aurora kinases SMITHKLINE BEECHAM (US) 2009-10-20 — — US disclosed
CN-101389324-A Azaindole inhibitors of aurora kinases SMITHKLINE BEECHAM CORP (US) 2009-03-18 — — CN disclosed
US-7495102-B2 Azaindole inhibitors of aurora kinases SMITHKLINE BEECHAM CORPORATION (US) 2009-02-24 — — US disclosed
US-20080306120-A1 Treating a solid tumor cancer and a hematological cancer by administering N'-{4-[4-(2-{3-[(dimethylamino)methyl]phenyl}-1H-pyrrolo[2,3-b]pyridin-4-yl)-1-ethyl-1H-pyrazol-3-yl]phenyl}-N,N-dimethylurea; antitumor, -carcinogenic, proliferative agents; antiinflammatory agents; autoimmune diseases; fungicides GLAXOSMITHKLINE LLC 2008-12-11 — — US disclosed
EP-1962830-A2 AZAINDOLE INHIBITORS OF AURORA KINASES SmithKline Beecham Corporation (US) 2008-09-03 — — EP disclosed
US-7419988-B2 Azaindole inhibitors of aurora kinases SMITHKLINE BEECHAM CORP (US) 2008-09-02 — — US disclosed
US-20080081808-A1 AZAINDOLE INHIBITORS OF AURORA KINASES SMITHKLINE BEECHAM CORPORATION 2008-04-03 — — US disclosed
US-20080004308-A1 AZAINDOLE INHIBITORS OF AURORA KINASES GLAXOSMITHKLINE LLC 2008-01-03 — — US disclosed
US-7282588-B2 Azaindole inhibitors of aurora kinases SMITHKLINE BEECHAM (US) 2007-10-16 — — US disclosed
WO-2007076348-A2 AZAINDOLE INHIBITORS OF AURORA KINASES SMITHKLINE BEECHAM CORPORATION (US) 2007-07-05 — — WO disclosed
US-20070149561-A1 AZAINDOLE INHIBITORS OF AURORA KINASES GLAXOSMITHKLINE LLC 2007-06-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070149561-A1 AZAINDOLE INHIBITORS OF AURORA KINASES AURKA, AURKC, AURKB AURKA 1/4885AURKB 3/4885INCENP 166/4885
US-20080081808-A1 AZAINDOLE INHIBITORS OF AURORA KINASES AURKA, AURKC, AURKB AURKA 1/4885AURKB 3/4885INCENP 166/4885
US-20080004308-A1 AZAINDOLE INHIBITORS OF AURORA KINASES AURKA, AURKC, AURKB AURKA 1/4885AURKB 3/4885INCENP 166/4885
US-20080306120-A1 Treating a solid tumor cancer and a hematological cancer by administering N'-{4-[4-(2-{3-[(dimethylamino)methyl]phenyl}-1H-pyrrolo[2,3-b]pyridin-4-yl)-1-ethyl-1H-pyrazol-3-yl]phenyl}-N,N-dimethylurea; antitumor, -carcinogenic, proliferative agents; antiinflammatory agents; autoimmune diseases; fungicides AURKA, AURKC, AURKB AURKA 1/4885AURKB 3/4885INCENP 646/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback